BioStock: Saniona’s CEO: “financing will bring SAN711 towards proof of concept”

Saniona recently unveiled two new clinical development candidates, expanding its repertoire in ion channel modulation for epilepsy and other neurological disorders. Beyond epilepsy, Saniona manages four clinical programmes, aimed at collaboration opportunities. To propel these assets and potentially forge strategic partnerships, Saniona is carrying out a 140 million SEK rights issue. BioStock talked to Saniona's CEO Thomas Feldthus to learn more.

Read the interview Thomas Feldthus with at biostock.se:

Saniona’s CEO: “financing will bring SAN711 towards proof of concept” - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/